23 patents
Utility
Engineered cascade components and cascade complexes
17 Jan 23
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 21 Sep 20
Utility
Engineered nucleic acid-targeting nucleic acids
22 Nov 22
The present disclosure provides engineered polynucleotide sequences that form scaffolds and nucleoprotein complexes comprising such engineered polynucleotide sequences that form scaffolds and nucleic acid binding proteins.
Paul Daniel Donohoue, Andrew Paul May
Filed: 4 Oct 18
Utility
Humanized BCMA antibody and BCMA-CAR-T cells
18 Oct 22
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 21 Mar 22
Utility
Methods of use of CRISPR CPF1 hybrid DNA/RNA polynucleotides
4 Oct 22
The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
Andrew Paul May, Paul Daniel Donohoue
Filed: 22 Mar 21
Utility
Compositions and methods of nucleic acid-targeting nucleic acids
26 Apr 22
This disclosure provides for compositions and methods for the use of nucleic acid-targeting nucleic acids and complexes thereof.
Andrew Paul May, Rachel E. Haurwitz, Jennifer A. Doudna, James M. Berger, Matthew Merrill Carter, Paul Daniel Donohoue
Filed: 4 Nov 16
Utility
CRISPR hybrid DNA/RNA polynucleotides and methods of use
1 Feb 22
The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
Andrew Paul May, Paul Daniel Donohue
Filed: 31 Oct 19
Utility
Engineered nucleic-acid targeting nucleic acids
18 Jan 22
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 19 Jun 20
Utility
Methods for using DNA repair for cell engineering
26 Oct 21
Methods for gene editing and predicting non-random editing events are described.
Daniel Capurso, Andrew P. May, Megan Van Overbeek
Filed: 21 Feb 17
Utility
BCMA-CAR-natural killer (NK) cells and methods related thereto
12 Oct 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 21 May 21
Utility
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
7 Sep 21
The present specification discloses engineered Type II CRISPR-Cas9 systems comprising split-nexus Cas9-associated polynucleotides (sn-casPNs), including systems comprising three split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN/sn3-casPN) and systems comprising two split-nexus Cas9-associated polynucleotides (sn1-casPN/sn2-casPN).
Paul Daniel Donohoue, Andrew Paul May
Filed: 28 Apr 18
Utility
Humanized BCMA antibody and BCMA-CAR-T cells
1 Jun 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 13 Jan 21
Utility
Engineered nucleic acid-targeting nucleic acids
11 May 21
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 11 Mar 20
Utility
Method of target cleaving using CRISPR hybrid DNA/RNA polynucleotides
27 Apr 21
The present disclosure provides DNA-guided CRISPR systems; polynucleotides comprising DNA, RNA and mixtures thereof for use with CRISPR systems; and methods of use involving such polynucleotides and DNA-guided CRISPR systems.
Andrew Paul May, Paul Daniel Donohoue
Filed: 28 Jul 20
Utility
Modified cascade ribonucleoproteins and uses thereof
23 Mar 21
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 26 Jun 20
Utility
Humanized BCMA antibody and BCMA-CAR-T cells
23 Feb 21
The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 3 and VL having the amino acid sequence of SEQ ID NO: 5.
Lijun Wu, Vita Golubovskaya
Filed: 2 Sep 20
Utility
Engineered cascade components and cascade complexes
21 Sep 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 18 Mar 20
Utility
Modified cascade ribonucleoproteins and uses thereof
13 Jul 20
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cash which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity.
Stan Johan Jozef Brouns, John van der Oost
Filed: 27 Aug 19
Utility
Engineered nucleic-acid targeting nucleic acids
13 Jul 20
The present disclosure provides engineered cross-type-nucleic-acid targeting nucleic acids and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Nov 19
Utility
Engineered cascade components and cascade complexes
23 Mar 20
The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides.
Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
Filed: 27 Oct 19
Utility
Engineered nucleic acid-targeting nucleic acids
16 Mar 20
The present disclosure provides engineered Class 2 CRISPR-Cas-associated discontinuous first-stem nucleic-acid targeting nucleic acids, nucleoprotein complexes comprising these nucleic acids, and compositions thereof.
Paul Daniel Donohoue, Andrew Paul May
Filed: 17 Oct 17